Crizotinib synergizes with cisplatin in preclinical models of ovarian cancer

Crizotinib, a small molecule inhibitor of anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1) and c-MET (also called MET or hepatocyte growth factor receptor), has been approved by the Food and Drug Administration for the treatment of patients with advanced non-small cell lung cancer whose tum...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Am J Transl Res
Hoofdauteurs: Huang, Xiao-Xiu, Xie, Feng-Feng, Hou, Li-Jiao, Chen, Xiu-Xiu, Ou, Rong-Ying, Yu, Jiang-Tao, Qiu, Jian-Ge, Zhang, Wen-Ji, Jiang, Qi-Wei, Yang, Yang, Zheng, Di-Wei, Chen, Yao, Huang, Jia-Rong, Wang, Kun, Wei, Meng-Ning, Li, Wen-Feng, Shi, Zhi, Yan, Xiao-Jian
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: e-Century Publishing Corporation 2017
Onderwerpen:
Original Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5411916/
https://ncbi.nlm.nih.gov/pubmed/28469773
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items